"Increasing HIV prevention and treatment options make it more important than ever to get tested and know your status.
September 27 is National Gay Men's HIV/AIDS Awareness Day, a time to reflect on the heavy toll of HIV among gay and bis"...
The highest single dose administered in clinical trials was 1,200 mg. The dose-limiting adverse event was postural hypotension, which was observed at 600 mg. While the recommended dose for SELZENTRY in patients receiving a CYP3A inducer without a CYP3A inhibitor is 600 mg twice daily, this dose is appropriate due to enhanced metabolism.
Prolongation of the QT interval was seen in dogs and monkeys at plasma concentrations 6 and 12 times, respectively, those expected in humans at the intended exposure of 300 mg equivalents twice daily. However, no significant QT prolongation was seen in the trials in treatment-experienced subjects with HIV using the recommended doses of maraviroc or in a specific pharmacokinetic trial to evaluate the potential of maraviroc to prolong the QT interval [see CLINICAL PHARMACOLOGY].
There is no specific antidote for overdose with maraviroc. Treatment of overdose should consist of general supportive measures including keeping the patient in a supine position, careful assessment of patient vital signs, blood pressure, and ECG.
If indicated, elimination of unabsorbed active maraviroc should be achieved by emesis. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Hemodialysis had a minimal effect on maraviroc clearance and exposure in a trial in subjects with ESRD [see CLINICAL PHARMACOLOGY].
SELZENTRY should not be used in patients with severe renal impairment or end-stage renal disease (ESRD) (CrCl < 30 mL/min) who are taking potent CYP3A inhibitors or inducers.
Last reviewed on RxList: 4/11/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Selzentry Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.